Literature DB >> 12403187

Interexaminer agreement for muscle palpation procedures: the efficacy of a calibration program.

Paulo César Rodrigues Conti1, Carlos Neanes dos Santos, José Roberto Pereira Lauris.   

Abstract

The purpose of this study is to assess the muscle palpation interexaminer agreement after a calibration program and to determine differences between time, groups of muscles, or side examined. A sample of 32 individuals, matched for sex, was divided into two groups: symptomatic (16 patients presenting with myogenic TMD) and asymptomatic (16 subjects with no TMD symptoms). Palpation procedures were performed three different times by four calibrated examiners, in masticatory and cervical muscles. The presence or severity of tenderness was judged by an ordinal scale (from "0" to "3"). Kendall's concordance test measured agreement between examiners. The sternocleidomastoid muscle showed the highest agreement (0.84), while the worst result was detected for the origin of the masseter (0.56). Levels of agreement for all muscles were considered fair and excellent, regardless of the time of examination or the side analyzed.

Entities:  

Mesh:

Year:  2002        PMID: 12403187     DOI: 10.1080/08869634.2002.11746221

Source DB:  PubMed          Journal:  Cranio        ISSN: 0886-9634            Impact factor:   2.020


  3 in total

1.  [Influence of botulinum toxin on myogenous facial pain].

Authors:  H Seedorf; R Leuwer; A Bussopulos; C Fenske; H D Jüde
Journal:  Schmerz       Date:  2005-02       Impact factor: 1.107

2.  The Research Diagnostic Criteria For Temporomandibular Disorders. II: reliability of Axis I diagnoses and selected clinical measures.

Authors:  John O Look; Mike T John; Feng Tai; Kimberly H Huggins; Patricia A Lenton; Edmond L Truelove; Richard Ohrbach; Gary C Anderson; Eric L Shiffman
Journal:  J Orofac Pain       Date:  2010

3.  DC/TMD Examiner Protocol: Longitudinal Evaluation on Interexaminer Reliability.

Authors:  Marit Slåttelid Skeie; Paula Frid; Manal Mustafa; Jörg Aßmus; Annika Rosén
Journal:  Pain Res Manag       Date:  2018-09-26       Impact factor: 3.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.